PRODUCT SHEET XENOGEN Bioware Cell Line MDA-MB...
4
PRODUCT SHEET Bioware ® Cell Line MDA-MB- 231 -luc-D3 H 1 XENOGEN Discovery in the Living Organism ® Designation: MDA-MB-231-luc-D3H1 Tissue: Human: adenocarcinoma; mammary gland; pleura effusion Parental Line Source: ATCC (HTB-26) Bioluminescence In Vitro: 150–200 photons / sec / cell, subject to imaging and culturing conditions In Vivo Models Tested: Nude (Harlan): mammary fat pad – lymph node metastasis, and intracardiac – multiple metastasis; Nude-beige (CR): mammary fat pad – lymph node and lung metastasis Model Description MDA-MB-231-D3H1is a luciferase expressing cell line that was derived from MDA-MD- 231 human adenocarcinoma cells by stable transfection of the North American Firefly Luciferase gene expressed from the SV40 promoter. MDA-MB-231-D3H1 cells are derived XENOGEN CORPORATION I N VIVO B IOPHOTONIC I MAGING TECHNOLOGIES MDA-MB-231-luc-D3H1 Applications m Experimental metastasis model m Orthotopic mammary fat pad model with metastasis Xenogen’s Bioware ® cell line models offer the ability to: m Monitor tumor growth and metastases in vivo m Quantify tumor burden in the whole animal test subject m Follow responses to therapeu- tic treatments non-invasively in longitudinal studies using the same cohorts of mice Murine Pathogen Free All Xenogen cell lines are confirmed to be pathogen free by the IMPACT Profile 1 (PCR) at the University of Missouri Research Animal Diagnostic and Investigative Laboratory. Figure 1. MDA-MB-231-luc-D3H1 cells (2x10 6 ) are injected into the mammary fat pad of female nude mice (Harlan). Tumor growth is monitored weekly for 8 weeks by in vivo imaging and caliper measurements (LxWxD). In vivo imaging demonstrates the progression of MDA-MB-231-luc tumors in the mammary fat pad of female nude mice (Harlan). The correlation between mean tumor volume and mean bioluminescence is 0.9919. Ventral View Figure 1. Orthotopic Tumor Growth– Harlan Nude Mice MDA-MB-231-luc-D3H1, 2x10 6 Cells, Mammary Fat Pad p/s/cm 2 /sr 100 60 x 10 6 80 20 40 Week 2 Week 5 Week 8 Week 0 100 200 300 400 500 600 800 700 0 2 1 3 4 5 7 9 6 8 10 Tumor Volume (mm 3 ) Week 0.0e+00 2.0e + 09 1.5e + 09 3.0e + 09 2.5e + 09 4.0e + 09 3.5e + 09 5.0e + 09 4.5e + 09 1.0e + 09 5.0e + 08 0 2 4 1 3 6 7 5 8 9 10 Photons/s 0.0e+00 2.0e + 09 1.5e + 09 3.0e + 09 2.5e + 09 4.0e + 09 3.5e + 09 1.0e + 09 5.0e + 08 Mean Tumor Volume (mm 3 ) 0 100 200 300 400 500 700 600 Mean Photons/s R 2 = 0.9919 Mean Tumor Volume Mean Tumor Bioluminescence Correlation
Transcript of PRODUCT SHEET XENOGEN Bioware Cell Line MDA-MB...
PRODUCT SHEETBioware® Cell Line MDA-MB-231-luc-D3H1XENOGEN
Discovery in the Living Organism®
Designation: MDA-MB-231-luc-D3H1Tissue: Human: adenocarcinoma; mammary gland;
pleura effusionParental Line Source: ATCC (HTB-26)Bioluminescence In Vitro: 150–200 photons/sec/cell, subject to
imaging and culturing conditionsIn Vivo Models Tested: Nude (Harlan): mammary fat pad – lymph node
metastasis, and intracardiac – multiple metastasis;Nude-beige (CR): mammary fat pad – lymph node and lung metastasis
Model DescriptionMDA-MB-231-D3H1is a luciferase expressing cell line that was derived from MDA-MD-231 human adenocarcinoma cells by stable transfection of the North American FireflyLuciferase gene expressed from the SV40 promoter. MDA-MB-231-D3H1 cells are derived
XENOGEN CORPORATION IN VIVO BIOPHOTONIC IMAGING TECHNOLOGIES
MDA-MB-231-luc-D3H1Applicationsm Experimental
metastasis modelm Orthotopic mammary
fat pad model with
metastasis
Xenogen’s Bioware® cell line
models offer the ability to:m Monitor tumor growth
and metastases in vivo
m Quantify tumor burden in
the whole animal test subjectm Follow responses to therapeu-
tic treatments non-invasively in
longitudinal studies using the
same cohorts of mice
Murine Pathogen FreeAll Xenogen cell lines are confirmed
to be pathogen free by the IMPACT
Profile 1 (PCR) at the University of
Missouri Research Animal Diagnostic
and Investigative Laboratory.
Figure 1. MDA-MB-231-luc-D3H1 cells (2x106) are injected into the mammary fat pad of female nude mice(Harlan). Tumor growth is monitored weekly for 8 weeks by in vivo imaging and caliper measurements (LxWxD). In vivo imaging demonstrates the progression of MDA-MB-231-luc tumors in the mammary fat pad of female nude mice (Harlan). The correlation between mean tumor volume and mean bioluminescence is 0.9919.
Ventral View
Figure 1.Orthotopic Tumor Growth– Harlan Nude Mice
MDA-MB-231-luc-D3H1, 2x106 Cells, Mammary Fat Pad
p/s/cm2/sr
100
60 x 106
80
20
40
Week 2 Week 5 Week 8
Week
0
100
200
300
400
500
600
800
700
0 21 3 4 5 7 96 8 10
Tum
or
Volu
me
(mm
3)
Week
0.0e + 00
2.0e + 09
1.5e + 09
3.0e + 09
2.5e + 09
4.0e + 09
3.5e + 09
5.0e + 09
4.5e + 09
1.0e + 09
5.0e + 08
0 2 41 3 6 75 8 9 10
Pho
tons/
s
0.0e + 00
2.0e + 09
1.5e + 09
3.0e + 09
2.5e + 09
4.0e + 09
3.5e + 09
1.0e + 09
5.0e + 08
Mean Tumor Volume (mm3)
0 100 200 300 400 500 700600
Mea
n P
ho
tons/
s
R2=0.9919
Mean Tumor Volume Mean Tumor Bioluminescence Correlation
MDA-MB-231-luc-D3H1 Bioware® Cell Line Product Sheet Page 2 of 4XENOGENDiscovery in the Living Organism®
XENOGEN CORPORATION IN VIVO BIOPHOTONIC IMAGING TECHNOLOGIES
Figure 2. MDA-MB-231-luc-D3H1 cells (2x106) are injected orthotopically into the abdominal mammary fat pad of female nude mice (Harlan) (n=7). Mice are imaged weekly from the ventral side with the primary tumors shielded in order to detect low signals from secondary metastases. Selected tissues are analyzed by ex vivoimaging and processed for subsequent histology. Metastatic signals begin to appear after 6–7 weeks. By week 7,lymph node metastases are detected in vivo in 88% (6/7) of mice.
Ventral ViewFemale Nude
Mouse (Harlan)
Figure 2.Spontaneous Metastases from an Orthotopic Mammary Fat Pad Implant
MDA-MB-231-luc-D3H1, 2x106 Cells
5000
3000
4000
1000
2000
In Vivo Image
Brachial Lymph Node
1000
600
800
200
400
Ex Vivo Image
Right BrachialLymph Node
Micrometastasis in Right Brachial
Lymph Node, 200x
Histopathologycounts
from a primary orthotopic tumor of MDA-MB-231-luc-D3 cells. This cell line can be used in vivo to establish:m Experimental metastasis model (intravenous and intracardiac)m Orthotopic mammary fat pad model with metastasis
Dorsal View
MDA-MB-231-luc-D3H1, 2x106 Cells
5000
3000
4000
1000
2000
Day 0250
200
100
150
50
Day 75000
3000
4000
1000
2000
Week 85000
3000
4000
1000
2000
Week 10
Ventral View
5000
3000
4000
1000
2000
Day 0250
200
100
150
50
Day 75000
3000
4000
1000
2000
Week 85000
3000
4000
1000
2000
Week 10
Figure 3.Intravenous Injection: Experimental Metastasis in Nude-bg Mice (CR)
Figure 3. MDA-MB-231-luc-D3H1 cells (2x106) are injected intravenously through the tail vein of female nudebeige mice (Charles River) (n=10) to allow colonization of the lungs. Mice are imaged from dorsal and ventral viewsonce a week from day 0 to week 20. Metastatic signals begin to appear at week 5. Most mice (8/10) develop theexpected lung colonization. The value of whole body imaging is evident from the additional detection of metastaticsites in pancreas and bone. These secondary metastases are confirmed by ex vivo imaging and histopathology.
counts
L. Lung R. Lung
Pancreas
Spleen
L. Lung R. Lung
Pancreas
Bone orTissue
Week 10 Signals– Left Lung
– Right Lung
– Pancreas
– Spine
Week 10 Signals– Left Lung
– Right Lung
– Pancreas
MDA-MB-231-luc-D3H1 Bioware® Cell Line Product Sheet Page 3 of 4XENOGENDiscovery in the Living Organism®
XENOGEN CORPORATION IN VIVO BIOPHOTONIC IMAGING TECHNOLOGIES
Figure 4. MDA-MB-231-luc-D3H1 cells (1x105) are injected into the left ventricle of female nude mice (n=5).As shown, mice were imaged weekly from dorsal and ventral views for 10 weeks. Selected tissues are imaged exvivo to confirm in vivo signals. Metastatic signals begin to appear after 5 weeks. By week 10, metastases aredetected in vivo in 80% of mice (4/5).
Ventral View
MDA-MB-231-luc-D3H1, 1x105 Cells
p/s/cm2/sr
20000
10000
15000
5000
Day 0
p/s/cm2/sr
5
3 x 106
4
1
0
2
Week 1
Dorsal View
Figure 4.Intracardiac Injection: Experimental Metastasis in Nude Mice (Harlan)
p/s/cm2/sr
5
3 x 106
4
1
0
2
Week 5
p/s/cm2/sr
5
3 x 106
4
1
0
2
Week 7
p/s/cm2/sr
5
3 x 106
4
1
0
2
Week 10
p/s/cm2/sr
1.0
0.6 x 106
0.8
0.2
0.4
p/s/cm2/sr
1.0
0.6 x 106
0.8
0.2
0.4
p/s/cm2/sr
1.0
0.6 x 106
0.8
0.2
0.4
p/s/cm2/sr
1.0
0.6 x 106
0.8
0.2
0.4
References 1. Scatena CD, Hepner MA, Oei YA, Dusich JM, Yu SF, Purchio T, Contag PR, Jenkins
DE. Imaging of Bioluminescent LNCaP-luc-M6 Tumors: A New Animal Model for theStudy of Metastatic Human Prostate Cancer. Prostate 2004 May 15; 59(3): 292–303.
2. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. In Vivo Monitoring of TumorRelapse and Metastasis Using Bioluminescent PC-3M-luc-C6 cells in Murine Models of Human Prostate Cancer. Clin Exp Metastasis 2003; 20(8): 745–56.
3. Jenkins DE, Oei Y, Hornig Y, Yu SF, Dusich J, Purchio T, Contag PR. BioluminescentImaging (BLI) to Improve and Refine Traditional Murine Models of Tumor Growth and Metastasis. Clin Exp Metastasis 2003; 20(8): 733–44.
4. Murray LJ, et al. SU11248 Inhibits Tumor Growth and CSF-1R-dependent Osteolysis in an Experimental Breast Cancer Bone Metastasis Model. Clin Exp Metastasis. 2003; 20(8):757–66.
5. Mendel DB, et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine KinaseInhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived GrowthFactor Receptors: Determination of a Pharmacokinetic/pharmacodynamic Relationship.Clin Cancer Res. 2003 Jan; 9(1): 327-37.
MDA-MB-231-luc-D3H1 Bioware® Cell Line Product Sheet Page 4 of 4XENOGENDiscovery in the Living Organism®
Contact Information
Please call 1.877.936.6436 or e-mail: [email protected] Corporation, 860 Atlantic Avenue, Alameda, California 94501 www.xenogen.com
© Xenogen Corporation, 2004. All rights reserved. XCPBO04-1104A. Trademarks: Xenogen, Discovery in the Living Organism,Bioware, IVIS, Living Image and LPTA are trademarks and/or trade names of Xenogen Corporation. All other company, product,and brand names are trademarks of their respective owners.
Credits: this Bioware® cell line information compiled by Yvette Hornig, Yoko Oei, Darlene Jenkins, Ph.D.
and Joycelyn Bishop. Figure 1: Exp. 078, Mouse 12, female nude mice, Harlan, n=7; Figure 2: Exp. 078,
Female nude mice, Mouse 12, Harlan, n=7; Figure 3: Exp. 053, Mouse 11, Female nude beige mice, Charles
River, n=10; Figure 4: Exp. 079, Mouse 40, Female nude mice, Harlan, n=5.
Bioware® cell lines contain a luciferase gene provided under a license from Promega Corporation. Under
the terms of that license, the use of these products and derivatives thereof is strictly limited to that of
a research reagent. No right to use these products for any diagnostic, therapeutic, or commercial appli-
cation will be conveyed to the customer of these products.
In vivo imaging in mammals is covered by one or more U.S. and foreign patents controlled by Xenogen
Corporation, including the following: U.S. patent numbers 6,649,143, 5,650,135, and 6,217,847, as well
as European Union patent number 0861093. A license from Xenogen Corporation is required to practice
under these patents.
References, Continued
6. Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS,Contag CH. Advancing Animal Models of Neoplasia Through In Vivo BioluminescenceImaging. Eur J Cancer 2002 Nov; 38(16): 2128-36.
7. Contag CH, Jenkins DE, Contag PR, Negrin R. Use of Reporter Genes for OpticalMeasurements of Neoplastic Disease In Vivo. Neoplasia 2000 Jan-Apr; 2(1-2): 41-52.
